BR100 Decreased By (-0.91%)
BR30 Decreased By (-1.47%)
KSE100 Decreased By (-0.78%)
KSE30 Decreased By (-0.75%)
AGHA 6.67 Decreased By ▼ -0.01 (-0.15%)
BECO 4.35 Decreased By ▼ -0.02 (-0.46%)
BML 56.17 Decreased By ▼ -1.15 (-2.01%)
BOP 30.12 Decreased By ▼ -0.23 (-0.76%)
CNERGY 12.98 Decreased By ▼ -0.14 (-1.07%)
CSIL 5.31 Decreased By ▼ -0.10 (-1.85%)
FCCL 51.65 Decreased By ▼ -1.14 (-2.16%)
FFL 14.49 Decreased By ▼ -0.23 (-1.56%)
FNEL 1.21 Increased By ▲ 0.09 (8.04%)
KEL 6.06 Decreased By ▼ -0.03 (-0.49%)
KOSM 5.84 Increased By ▲ 0.11 (1.92%)
LOTCHEM 26.17 Decreased By ▼ -0.29 (-1.1%)
MLCF 91.23 Decreased By ▼ -1.93 (-2.07%)
NBP 164.19 Decreased By ▼ -0.47 (-0.29%)
NCPL 53.18 Decreased By ▼ -2.48 (-4.46%)
NPL 59.12 Decreased By ▼ -2.04 (-3.34%)
OGDC 313.39 Decreased By ▼ -3.34 (-1.05%)
PACE 9.77 Decreased By ▼ -0.10 (-1.01%)
PAEL 35.24 Decreased By ▼ -0.39 (-1.09%)
PIBTL 14.71 Increased By ▲ 0.03 (0.2%)
PPL 221.36 Decreased By ▼ -5.55 (-2.45%)
PRL 91.22 Decreased By ▼ -1.80 (-1.94%)
PTC 59.19 Decreased By ▼ -1.07 (-1.78%)
SSGC 23.30 Decreased By ▼ -0.51 (-2.14%)
TBL 8.75 No Change ▼ 0.00 (0%)
TELE 7.61 Decreased By ▼ -0.19 (-2.44%)
TPL 22.03 Decreased By ▼ -0.32 (-1.43%)
TPLP 12.56 Decreased By ▼ -0.41 (-3.16%)
TREET 21.73 Decreased By ▼ -0.43 (-1.94%)
TRG 55.79 Decreased By ▼ -0.77 (-1.36%)
World

Thai PM gets AstraZeneca jab as country resumes rollout despite concerns

  • Thailand is already administering China's Sinovac vaccine, with millions more imported doses expected in the coming months.
Published Updated
By

BANGKOK: Thailand's prime minister on Tuesday received the AstraZeneca vaccine as the Southeast Asian nation began the drug's rollout, lifting a suspension that was triggered by European nations raising safety concerns.

The country became the first outside of Europe to temporarily delay the Covid-19 vaccine after several EU nations -- including Ireland, the Netherlands and Denmark -- moved to delay it due to reports that some recipients had suffered blood clots.

Thailand is already administering China's Sinovac vaccine, with millions more imported doses expected in the coming months.

But it was expected to add the Oxford/AstraZeneca injection to its vaccine options on Friday, before health authorities abruptly suspended it as a precaution.

By Monday, it had cleared its use after the World Health Organization, the European Medicines Agency and many countries, including Britain and Canada, declared it safe for use.

"Today, we will start injections on another vaccine. I think it will create confidence for people to get the vaccine," Thai premier Prayut Chan-O-Cha said.

The gruff former general's jab was initially scheduled for Friday but it was postponed at the last minute following the delay. The country's political leaders went ahead with their jabs on Tuesday.

"Everyone is fine. I am an example today for having AstraZeneca," the 67-year-old, who was the first person to receive the jab in the Southeast Asian country, said of his cabinet.

WHO safety experts were preparing to meet Tuesday over the vaccine melee as the three largest EU nations -- Germany, Italy and France -- followed other EU members in suspending the shot on Monday, dealing a blow to the global immunisation campaign.

The vaccine was developed by AstraZeneca and the University of Oxford in Britain, where more than 11 million doses have been administered apparently without any major problems.

Thailand is not set to start its own mass vaccination campaign until June, with more than 60 million shots planned through domestic production of the AstraZeneca vaccine.

But it is vaccinating essential workers and other groups with more than 100,000 AstraZeneca jabs imported for emergency use earlier this month.

AstraZeneca's shot, among the cheapest available, was billed as the vaccine of choice for poorer nations and the clot reports have had an impact beyond Europe.

Indonesia delayed its AstraZeneca rollout on Monday, and Venezuela announced it would not authorise the jab over fears of "complications".

Comments

Comments are closed for this article.